A shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development In October, the administration of U.S. President Donald Trump outlined a plan that, if implemented, would substantially lower the amount the U.S. government will pay drug-makers for certain pharmaceuticals covered by its Medicare plan. Though limited in scope,
Advertisement
